1-(2,4-ジフルオロフェニル)-3-{4-[(6,7-ジメトキシキノリン-4-イル)オキシ]-2-フルオロフェニル}尿素

1-(2,4-ジフルオロフェニル)-3-{4-[(6,7-ジメトキシキノリン-4-イル)オキシ]-2-フルオロフェニル}尿素 価格

1-(2,4-ジフルオロフェニル)-3-{4-[(6,7-ジメトキシキノリン-4-イル)オキシ]-2-フルオロフェニル}尿素 化学特性,用途語,生産方法

• 外観

  白色～うすい褐色, 結晶～粉末

• 溶解性

  ジメチルスルホキシドに可溶

• 使用

  Ki8751 is a potent and selective inhibitor of VEGFR2, PDGFRα and c-Kit with IC50 of 0.9 nM, 67 nM and 40 nM, respectively.

• 一般的な説明

  A cell-permeable quinolyloxyphenyl-urea compound that acts as a VEGFR-2-selective inhibitior in both cell-based (IC₅₀ = 0.9 nM in VEGF-induced receptor phosphorylation) and cell-free (IC₅₀ = 4.0 nM in kinase reactions) assays. It inhibits c-Kit, PDGFRα, and FGFR-2 only at much higher concentrations (IC₅₀ = 40, 67, and 170 nM, respectively, in cell-based assays), while exhibiting no effect against eight other commonly studied receptor and non-receptor kinases even at concentrations as high as 10 μM. Effectively blocks VEGF-dependent, but not VEGF-independent, cell proliferation in vitro and tumor growth in mice and rats (5 to 20 mg/kg, daily p.o.) in vivo.

• 生物活性

  Potent, selective inhibitor of VEGFR-2 tyrosine kinase (IC 50 = 0.9 nM). Displays some inhibitory activity towards c-Kit, PDGFR α and FGFR-2 (IC 50 values range from 40 to 170 nM) but is highly selective over other receptor tyrosine kinases (IC 50 > 10000 nM for FGFR-2, EGFR and HGFR). Inhibits VEGF-stimulated proliferation of human umbilical vein endothelial cells (HUVEC) and inhibits tumor growth in vivo ; antiangiogenic.

1-(2,4-ジフルオロフェニル)-3-{4-[(6,7-ジメトキシキノリン-4-イル)オキシ]-2-フルオロフェニル}尿素 生産企業

Global(120)Suppliers

228559-41-9, 1-(2,4-ジフルオロフェニル)-3-{4-[(6,7-ジメトキシキノリン-4-イル)オキシ]-2-フルオロフェニル}尿素 キーワード